menu
    • menu
    [{"orgOrder":0,"company":"Aguettant","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Sufentanil Citrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aguettant","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Aguettant \/ Aguettant","highestDevelopmentStatusID":"15","companyTruncated":"Aguettant \/ Aguettant"}]

    Find Clinical Drug Pipeline Developments & Deals by Aguettant

    Menu

    Aguettant

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aguettant

                            France arrow
                            EPSC
                            Not Confirmed

                            Aguettant

                            France arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : AcelRx Pharmaceuticals

                            Deal Size : $55.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in t...

                            Details : Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. In 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.

                            Product Name : Dsuvia

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 14, 2021

                            Lead Product(s) : Sufentanil Citrate,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : AcelRx Pharmaceuticals

                            Deal Size : $55.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth